^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LY4170156

    i
    Other names: LY4170156, MBK-103, MBK103, MBK 103, LY 4170156, LY-4170156
    Associations

    News

    Trials
    Company:
    Eli Lilly
    Drug class:
    Topoisomerase I inhibitor, Folate receptor 1-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    6ms
    A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=220, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open • Tumor cell • Metastases
    |
    LY4170156
    7ms
    A Study of LY4170156 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=220, Not yet recruiting, Eli Lilly and Company
    New P1 trial • Tumor cell • Metastases
    |
    LY4170156
    over1year
    MBK-103, a potent novel conjugation platform-based antibody-drug conjugate, changing therapeutic options in folate receptor alpha positive cancer patients (AACR 2023)
    The compound was also very well tolerated in cynomolgus monkeys with HNSTD at 50 mg/kg and even when administered repeatedly. High conjugation yields along with 100% homogeneity are major drivers of the successful ongoing manufacturing process with planned IND submission in Q4/2023.
    Clinical
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression • FOLR1 positive
    |
    LY4170156